APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer
H. Isozaki, A. Abbasi, N. Nikpour, A. Langenbucher, W. Su, M. Stanzione, H. Frisco-Cabanos, F. M. Siddiqui, N. Phan, P. Jalili, S. Oh, D. Timonina, S. Bilton, M. Gomez-Caraballo, H. L. Archibald, , A. N. Hata
This study shows that APOBEC3A mutagenesis driven by targeted therapies promotes drug resistance in non-small cell lung cancer.
bioRxiv · Jan 20, 2021Cancer Biology